it is amazing what people will latch on to
it will be interesting to see what VRTX has to say tonight as the street.com says it is holding an investor meeting tonight and will report additional data tomorrow morning
but one needs to consider that pegylated interferon alone can give a more than 80% SVR for type 4
so the new data that is considered to be so damaging for VRTX is actually for a genotype of HepC that is already very easy to treat with interferon alone
check it out for yourself
Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response.
Kamal SM, El Kamary SS, Shardell MD, Hashem M, Ahmed IN, Muhammadi M, Sayed K, Moustafa A, Hakem SA, Ibrahiem A, Moniem M, Mansour H, Abdelaziz M.
Department of Gastroenterology and Hepatology, Ain Shams University, Cairo, Egypt.
In patients chronically infected with hepatitis C virus (HCV) genotype 4, the optimum duration of therapy and the predictors of sustained virologic response (SVR) have not been adequately determined. In this study, 358 patients with chronic hepatitis C genotype 4 were randomly assigned to pegylated interferon (PEG-IFN) alpha-2b (1.5 mug/kg/week) plus oral ribavirin (10.6 mg/kg/day) for a fixed duration of 48 weeks (control group, n = 50) or for a variable duration (n = 318). In the variable-duration group, patients with undetectable HCV RNA at week 4 were treated for 24 weeks (group A, n = 69), patients with undetectable HCV RNA at week 12 were treated for 36 weeks (group B, n = 79), and the rest of the patients were treated for 48 weeks (group C, n = 160). The primary endpoint was SVR (undetectable HCV RNA 24 weeks after treatment cessation). Groups A-C and the control group had SVR rates of 86%, 76%, 56%, and 58%, respectively. After the study was controlled for predictors, a low baseline histologic grade and stage were associated with SVR (P < 0.029) in all groups. In addition, among patients in group C, older age (P = 0.04), a higher baseline body mass index (P = 0.013), and low baseline HCV RNA (P < 0.001) were also associated with SVR attainment. The incidence of adverse events and the rate of discontinuation were higher in patients in the variable-duration and fixed-duration groups treated for 48 weeks. Conclusion: In patients with chronic hepatitis C genotype 4 and undetectable HCV RNA at weeks 4 and 12, treatment with PEG-IFN alpha-2b and ribavirin for 24 weeks and 36 weeks, respectively, is sufficient. (HEPATOLOGY 2007.).
You shut up and go away. You are just a pity losser who lost the money in VRTX, but still live in a dream of speculation that someday, VRTX could make you a millionaire!Why you just go kiss the Boger brother and John Alam who already became a multi-millionaires 10 years ago and still trying to ripe off those pity investors.
I'm not supporting or disputing ANYONE here, but one thing I do know..the paradigm of 2's and 3's being easier to treat is changing...many more of them are doing 48 weeks now of SOC and more of them are having the virus come back after tx.
As a patient...I'm kind of feeling like when it rains, it pours. The market is TOTALLY overreacting to AASLD, it will take a couple of months to sort out the news coming out of the conference. Seems to be wonderful news for anyone with an untreated case of Hep C and there are about three million of those in the US alone, not so good for the million of us who are interferon resistant.
We all know Telaprevir will be approved and Vertex will pop a bit. But for how long? All this news is great for Hep C patients...but I feel a bit like road kill..so many circling now over my wasted carcass.
Baloney, you are full of it. My question to you had to do with backing up your statement that disontinuations due to lost to follow up and withdrawn consent were actually due to AEs. Show me the proof or shut up and go away.
My point to you is never investing in a speculation, but into a company with a real earning. VRTX has been out there for more than 20 years but had never made a penny of profit for their investors. It is ashame for the company's management team, especially, the Boger brothers.
If you bought ISRG this summer, you wouldn't have to spend time hanging on this board to defend your wrong investment. Speculation is far from making a real money, but just an empty dream and burst bubble.